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Abstract 
Background: Randomized, controlled cardiovascular outcome trials may not be fully representative of the man‑
agement of patients with type 2 diabetes across different geographic regions. We conducted analyses of data 
from the multinational CVD‑REAL consortium to determine the association between initiation of sodium–glucose 
cotransporter‑2 inhibitors (SGLT‑2i) and cardiovascular outcomes, including subgroup analyses based on patient 
characteristics.
Methods: De‑identified health records from 13 countries across three continents were used to identify patients 
newly‑initiated on SGLT‑2i or other glucose‑lowering drugs (oGLDs). Propensity scores for SGLT‑2i initiation were 
developed in each country, with 1:1 matching for oGLD initiation. In the matched groups hazard ratios (HRs) for 
hospitalization for heart failure (HHF), all‑cause death (ACD), the composite of HHF or ACD, myocardial infarction (MI) 
and stroke were estimated by country, and pooled using a weighted meta‑analysis. Multiple subgroup analyses were 
conducted across patient demographic and clinical characteristics to examine any heterogeneity in treatment effects.
Results: Following matching, 440,599 new users of SGLT‑2i and oGLDs were included in each group. Mean follow‑
up time was 396 days for SGLT‑2i initiation and 406 days for oGLDs initiation. SGLT‑2i initiation was associated with a 
lower risk of HHF (HR: 0.66, 95%CI 0.58–0.75; p < 0.001), ACD (HR: 0.52, 95%CI 0.45–0.60; p < 0.001), the composite of 
HHF or ACD (HR: 0.60, 95%CI 0.53–0.68; p < 0.001), MI (HR: 0.85, 95%CI 0.78–0.92; p < 0.001), and stroke (HR: 0.78, 95%CI 
0.72–0.85; p < 0.001); regardless of patient characteristics, including established cardiovascular disease, or geographic 
region.
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 




1 University of Leicester, University Road, Leicester LE1 7RH, UK
Full list of author information is available at the end of the article
Page 2 of 15Khunti et al. Cardiovasc Diabetol          (2021) 20:159 
Background
Despite recent improvements, cardiovascular dis-
ease  (CVD) remains the leading global cause of mortal-
ity and morbidity in patients with type 2 diabetes [1]. The 
prevalence of diabetes continues to increase, with the 
majority of people affected residing in the Asia–Pacific 
region, South East Asia and the Middle East [2–4]. How-
ever, global outcomes data are sparse for new therapies 
in people with type 2 diabetes, especially outside North 
America and Europe. Previous studies have shown large 
variations in the management of people with diabetes 
and the prevalence of complications [5, 6]. More recently, 
global collaborative studies have shown that there are 
differences in patient characteristics, treatment pat-
terns, and types of adverse CVD events experienced by 
patients in different regions and different ethnicities [7]. 
Moreover, results of randomized controlled cardiovas-
cular outcome trials have been criticised for not being 
representative of the management of people with type 
2 diabetes in real-world settings [8], with most patients 
being recruited in North America and Europe. Clini-
cians across other world regions are therefore cautious 
about generalizing the results of trials into their clinical 
practice.
Over recent years, there has been a number of studies 
reporting the comparative effectiveness of novel thera-
pies in the ‘real-world’ setting. Sodium–glucose cotrans-
poter-2 inhibitors (SGLT-2is) have now been studied 
in several cardiovascular outcome trials [9–13], with a 
recent systematic review and meta-analysis showing the 
benefits of this class of drugs on major cardiovascular 
events in people with established CVD, and on heart fail-
ure and renal outcomes in people with and without CVD 
[14]. We have previously conducted a number of phar-
maco-epidemiological studies (CVD-REAL—Compara-
tive Effectiveness of Cardiovascular Outcomes in New 
Users of Sodium–Glucose Cotransporter-2 Inhibitors) on 
the effectiveness of SGLT-2i in the real-world setting [15, 
16]. Although there were differences in point estimates 
across countries for some outcomes, the directionality of 
associations was consistent despite variable patient char-
acteristics, health care  settings, practice  patterns, and 
specific SGLT-2i compounds used.
In this study, we conducted further analyses of the larg-
est CVD-REAL dataset to date, to assess a broad range 
of cardiovascular outcomes, including hospitalization 
for heart failure, all-cause mortality, myocardial infarc-
tion, and stroke. Our additional aim was to use the large 
number of patients and events in this dataset to expand 
the results of CVD-REAL by examining SGLT2i effects 
across a broad range of subgroups including baseline 
therapies and other chronic multimorbidities. We also 




Analyses were conducted on de-identified health records 
from 13 countries (Australia, Canada, Denmark, Finland, 
Germany, Israel, Japan, Singapore, South Korea, Spain, 
Sweden, Taiwan, and the USA). Descriptions of the 
sources of data have been reported previously [16–19], 
apart from Finland which is included in Additional file: 
Data Sources 1.
Patient cohort
Patients with type 2 diabetes were identified using stand-
ard diagnosis codes (Additional file  1: Table  S1), except 
in Australia where this was based on physician or nurse 
educator clinical diagnosis of type 2 diabetes. All epi-
sodes of new initiation of either SGLT-2i or other glu-
cose-lowering drugs (oGLD) were selected within the 
country-specific date range for availability of SGLT-2i 
[Additional file  1: Table  S2; range: December 1, 2012 
(Denmark) to May 1, 2016 (Taiwan)]. Treatment ini-
tiation episodes were defined as written/dispensed pre-
scription (as initial or add-on therapy) for any SGLT-2i or 
oGLD, including fixed-dose combinations, without any 
use of the same therapy during the preceding 12 months; 
a patient might contribute with several episodes, every 
time the criteria of new user is met. Additional inclusion 
criteria were: age ≥ 18  years on the index date (defined 
as the prescription date for new initiation of an SGLT-2i 
or oGLD) and availability of historic data for more than 
1 year in the database before the index date. Patients with 
type 1 or gestational diabetes were excluded. Patients 
were followed from the index date until migration/leav-
ing the practice/database, last date of data collection, out-
come date, or censoring date [Additional file 1: Table S2; 
Conclusions: This CVD‑REAL study extends the findings from the SGLT‑2i clinical trials to the broader setting of an 
ethnically and geographically diverse population, and across multiple subgroups.
Trial registration NCT02993614
Keywords: Sodium–glucose cotransporter‑2 inhibitors, Cardiovascular outcomes, Heart failure, Type 2 diabetes
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range: December 31, 2014 (Australia) to November 30, 
2017 (Singapore)].
Outcomes
The outcomes were hospitalization for heart failure 
(HHF), all-cause death, the composite of HHF or  all-
cause death, non-fatal myocardial infarction, or non-fatal 
stroke. Outcomes were defined using primary discharge 
diagnosis codes (Additional file 1: Table S3) and validated 
independently in each country. Data regarding all-cause 
death were available from all countries; data for the other 
outcomes were available from all countries except Aus-
tralia. Additionally, in Japan and Singapore only infor-
mation on in-hospital deaths was available; however, 
in-hospital deaths represent the majority of fatal events 
in these countries according to the national statistics [20, 
21]. In Sweden and Denmark, HHF was defined by any 
hospital visit with a registered main diagnosis of heart 
failure [inpatient or outpatient visit; defined using diag-
nosis codes (Additional file 1: Table S3)].
Statistical analysis
Detailed statistical methods are described in a prior pub-
lication [15]. Briefly, baseline characteristics were ana-
lyzed using descriptive statistics. Categorical variables 
were described by frequencies and percentages, and 
mean ± standard deviation (SD) were used for continu-
ous variables. The overall mean across all databases was 
a summary estimate of country-specific means, weighted 
according to the number of patients in each database. 
The proportion of exposure time contributed by individ-
ual agents was summarized both overall and by country.
A non-parsimonious propensity score for initiat-
ing SGLT-2i was developed separately for each country. 
All available variables in each country that could affect 
treatment assignment or outcomes were included in the 
propensity score (Additional file  1: Table  S4; baseline 
comorbidity information was not available for Australia, 
although extensive medication data were available). 
Based on propensity scores, episodes of patients initiat-
ing SGLT-2i were matched 1:1 with episodes of initiat-
ing oGLD. The adequacy of matching was assessed by 
evaluating post-match standardized differences in patient 
characteristics (Table 1). A non-negligible imbalance was 
considered if a > 10% standardized difference occurred 
between the two groups post-match.
The incidence rate (IR) for each outcome was assessed 
by treatment group as the number of events divided by 
the total number of person-years at risk. The time to first 
event was compared between groups using Cox propor-
tional hazards models, presented as hazard ratios (HR; 
95%CI) for each outcome separately by country. The 
primary analysis used an intent-to-treat (ITT) approach 
where patients were followed from the start of index 
treatment until either occurrence of the first outcome 
event or the censoring date (whichever came first), 
regardless of whether index treatment was discontinued. 
The HRs for each endpoint from each individual coun-
try were then pooled for an overall weighted summary 
[22], using random-effects models with inverse variance 
weighting for each country [23].
Analyses for each outcome were also stratified accord-
ing to the presence of prior CVD [defined as history of 
myocardial infarction, unstable angina, heart failure, 
atrial fibrillation, stroke, percutaneous coronary inter-
vention (PCI) or coronary artery bypass graft (CABG)]; 
patient age and sex; history of heart failure, chronic kid-
ney disease (CKD), or cancer; baseline use of angioten-
sin-converting enzyme inhibitors (ACEi) or angiotensin 
receptor blockers (ARBs), β-blockers, high ceiling diuret-
ics, aldosterone antagonists, insulin, sulphonylureas, and 
statins.
Sensitivity analyses were performed in order to evalu-
ate the stability of the findings: data for the primary 
analysis were additionally adjusted for multiple covari-
ates [age, gender, frailty (defined as at least one hospi-
talization of at least three consecutive days during the 
year prior to index), history of heart failure, history of 
myocardial infarction, atrial fibrillation history, hyper-
tension (if available), obesity/BMI (if available), dura-
tion of diabetes (if available), and use of ACEi or ARBs, 
β-blockers,  Ca2+-channel blockers, statins, loop diuret-
ics and thiazide diuretics]; analyses were repeated using 
an on-treatment approach (follow-up censored at index 
treatment discontinuation).
Informed consent was not required, as the data were 
collected for clinical and administrative purposes and 
were analysed after de-identification. Analyses of data 
were conducted in accordance with local laws and regu-
lations, and received approvals from Scientific/Ethics/
Data Protection Committees in each country. Country-
specific analyses were conducted by independent aca-
demic/statistical groups in each country. Meta-analyses 
were conducted by Statisticon AB, Uppsala (Sweden) and 
validated by independent academic statisticians at Saint 
Luke’s Mid America Heart Institute, Kansas City, Mis-
souri (USA).
Role of funding source
This analysis was overseen by the CVD-REAL (Com-
parative Effectiveness of Cardiovascular Outcomes in 
New Users of Sodium–Glucose Cotransporter-2 Inhibi-
tors) Academic Scientific Committee, Study Group and 
Investigators, including members from the sponsor. The 
sponsor was involved in the design of the analysis, and 
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the collection/interpretation of data. No payment was 
received by any author for writing this manuscript. The 
corresponding author and senior author had full access 
to all data, and vouch for the accuracy and completeness 




A total of 9,631,497 patients who newly initiated either 
SGLT-2i or oGLD treatment during the study period was 
identified (Additional file  1: Figure S1); 477,894 (5.0%) 
were new users of SGLT-2i and 9,153,603 (95.0%) were 
new users of oGLD. Prior to propensity score matching, 
the patients who initiated SGLT-2i were younger, had 
slightly less prevalent heart failure, stroke and CKD at 
Table 1 Baseline characteristics for all 13 countries combined (post‑match)
All values are n (%) unless otherwise stated; the denominator varies between each variable due to data availability for each database; * ≥ 1 hospitalization of ≥ 3 
consecutive days during the year prior to index
ACE angiotensin converting enzyme, ARB angiotensin receptor blockers, CKD chronic kidney disease, CV cardiovascular, DPP-4i dipeptidyl peptidase-4 inhibitor, 
GLP-1RA glucagon-like peptide-1 receptor agonist, oGLD other glucose-lowering drug, PAD peripheral artery disease, SGLT-2 sodium–glucose cotransporter-2, std diff 
standardized difference, SU sulfonylureas, TZD thiazolidinediones
SGLT-2 inhibitor (N = 440,599) oGLD (N = 440,599) std diff (%)
Age, years 58.0 (11.6) 57.8 (12.7) 1.4
Women 193,825 (44.0) 194,123 (44.1) 0.1
CV‑history 134,331 (31.5) 129,993 (30.5) 2.2
 Myocardial infarction 19,346 (4.5) 18,968 (4.4) 0.4
 Unstable angina 22,030 (5.2) 21,489 (5.0) 0.6
 Heart failure 32,736 (7.7) 31,948 (7.5) 0.7
 Atrial fibrillation 18,448 (4.3) 17,910 (4.2) 0.6
 Stroke 47,437 (11.1) 45,353 (10.6) 1.6
PAD 22,391 (5.2) 22,054 (5.2) 0.4
Microvascular disease 218,288 (51.1) 214,311 (50.2) 1.9
CKD 24,528 (5.7) 23,969 (5.6) 0.6
Frailty (yes)* 36,736 (8.9) 36,498 (8.8) 0.2
Glucose‑lowering therapies
 Metformin 334,441 (75.9) 335,731 (76.2) 0.7
 SU 197,712 (44.9) 197,117 (44.7) 0.3
 DPP‑4i 205,550 (46.7) 203,469 (46.2) 0.9
 TZD 48,775 (11.1) 46,710 (10.6) 1.5
 GLP‑1RA 36,903 (8.4) 34,033 (7.7) 2.4
 Insulin 109,470 (24.8) 104,973 (23.8) 2.4
Anti‑hypertensive therapy 308,944 (70.1) 304,417 (69.1) 2.2
 Loop diuretics 38,852 (8.8) 37,785 (8.6) 0.9
 Low ceiling diuretics 54,358 (12.3) 53,731 (12.2) 0.4
 ACEi 97,176 (22.1) 97,019 (22.0) 0.1
 ARBs 183,048 (41.5) 181,136 (41.1) 0.9
Statin therapy 288,674 (65.5) 286,787 (65.1) 0.9
Beta blockers 114,079 (25.9) 112,092 (25.4) 1.0
Aldosterone antagonists 14,215 (3.2) 13,998 (3.2) 0.3
Index year
 2012 20 (0.0) 109 (0.1) 2.6
 2013 12,006 (5.5) 11,889 (5.4) 0.2
 2014 64,187 (16.2) 63,126 (15.9) 0.7
 2015 120,957 (30.8) 121,370 (30.9) 0.2
 2016 206,590 (49.3) 205,948 (49.2) 0.3
 2017 36,839 (20.7) 38,157 (21.4) 1.8
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baseline and greater use of statins, ACEis and low-ceiling 
diuretics (Additional file  1: Table  S5). Patients initiated 
on SGLT-2i were also more likely to be receiving other 
glucose-lowering drugs at baseline (Additional file  1: 
Table S5).
Following propensity score matching, there were 
440,599 new initiators of SGLT-2i and 440,599 new ini-
tiators of oGLDs (Additional file  1: Figure S1) and the 
baseline characteristics were well-balanced (Table  1). 
In both groups, the mean age was 58  years, 44% were 
women, and 31% had established CVD; 65% of patients 
received statins, 69% antihypertensive medications, 
and 76% metformin (Table  1). The distribution of spe-
cific SGLT-2i compounds initiated is shown in Addi-
tional file  1: Table  S6; dapagliflozin contributed 60% 
of total exposure time, followed by canagliflozin (20%) 
and empagliflozin (14%), with other SGLT-2is providing 
smaller contributions. The distribution of oGLD by class 
is shown in Additional file 1: Table S7; the DPP-4i class 
contributed to 25% of the oGLD exposure time, followed 
by insulin (18%), SUs (18%), metformin (13%) and TZDs 
(11%); other classes (GLP-1 RA, acarbose and metiglin-
ides) contributed < 10% each and made up the remainder.
Pre-propensity match, the proportion of new SGLT-2i 
episodes that were identified for each included country is 
shown in Fig. 1 as a function of time. For the countries 
included in this study, the proportion of new initiations 
that were SGLT-2i increased consistently over time; in 
North America, the proportion increased until 2015, with 
a slight decrease thereafter. When all countries included 
in this analysis were considered together, the proportion 
of new SGLT-2i initiation increased from around 3% of 
all new initiations in 2013, to about 15% in 2017 (Fig. 1).
Outcomes
The mean follow-up time for the primary ITT analysis 
was 396 days for SGLT-2i and 406 days for oGLDs initia-
tions (Additional file 1: Table S8).
During 914,208 patient-years of follow-up there were 
9121 events of HHF (3913 in the SGLT-2i group and 5208 
in the oGLD group; Additional file 1: Table S9). Initiation 
of SGLT-2i was associated with a lower risk of HHF (ITT-
unadjusted pooled HR: 0.66, 95%CI 0.58–0.75; p < 0.001; 
Fig.  2). While there was heterogeneity, there were con-
sistent associations between use of SGLT2i and lower 
risk of heart failure in all of the 13 countries (Additional 
file 1: Figure S2A).
During 968,452 patient-years of follow-up, there were 
10,252 events of all-cause death (3712 in the SGLT-2i 
group and 6540 in the oGLD group; Additional file  1: 
Table  S9). Initiation of SGLT-2i was associated with a 
lower risk of all-cause death (ITT-unadjusted pooled 
HR: 0.52, 95%CI 0.45–0.60; p < 0.001; Fig. 2). While there 
was heterogeneity, there were consistent associations 
between use of SGLT2i and lower risk of all-cause death 
in all of the 13 countries (Additional file 1: Figure S2B).
For the composite outcome of HHF or all-cause death, 
there were 17,207 events (6932 in the SGLT-2i group and 
10,275 in the oGLD group) over 898,869 patient-years 
of follow-up (Additional file  1: Table  S9). Initiation of 
SGLT-2i was associated with a lower risk of the compos-
ite of HHF or all-cause death (ITT-unadjusted pooled 
HR: 0.60, 95%CI 0.53–0.68; p < 0.001; Fig. 2). While there 
was heterogeneity, there were consistent associations 
between use of SGLT2i and lower risk of HHF or all-
cause death in all of the 13 countries (Additional file  1: 
Figure S2C).
For myocardial infarction, there were 4880 events 
(2203 in the SGLT-2i group and 2677 in the oGLD group) 
over 916,305 patient-years of follow-up (Additional file 1: 
Table  S9): initiation of SGLT-2i was associated with a 
lower risk of myocardial infarction (ITT-unadjusted 
pooled HR: 0.85, 95%CI 0.78–0.92; p < 0.001; Fig. 2; Addi-
tional file 1: Figure S2D).
For stroke, there were 9111 events (3981 in the SGLT-
2i group and 5130 in the oGLD group) over 913,571 
patient-years of follow-up (Additional file  1: Table  S9): 
initiation of SGLT-2i was associated with a lower risk of 
stroke (ITT-unadjusted pooled HR: 0.78, 95%CI 0.72–
0.85; p < 0.001; Fig. 2; Additional file 1: Figure S2E). There 
was no evidence of treatment heterogeneity across coun-
tries for the outcomes of myocardial infarction or stroke 
(p for interaction > 0.07).
Subgroup and sensitivity analyses
Analyses of data stratified by baseline characteristics con-
tinued to favor SGLT-2is over oGLD for the outcomes 
of HHF, all-cause death, composite of HHF or all-cause 
death, myocardial infarction and stroke across all sub-
groups, with very few significant interactions (Fig. 3).
Findings similar to the primary analyses were seen 
upon multivariable adjustment and in the on-treatment 
analyses (Additional file 1: Figures S3-S5).
Discussion
In this latest update to the CVD-REAL study, that 
included nearly 10 million people from 13 countries, 
we report a number of notable findings. First, we show 
temporal trends in the prescribing of SGLT-2i thera-
pies across three continents from 2012 to 2017, high-
lighting large global variations. Second, we show that 
in an analysis of data from a much larger number of 
countries and patients than previously reported, ini-
tiation of SGLT-2i therapy was associated with signifi-
cantly lower risk of HHF, all-cause death, composite 
of HHF or all-cause death, myocardial infarction and 
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Fig. 1 Trends in proportion of new user episodes which were SGLT‑2i by A country and B overall in 2012–2017 (pre‑propensity matching). SGLT-2i 
sodium–glucose cotransporter‑2 inhibitor
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stroke, compared with the initiation of oGLDs. Finally, 
we demonstrate that the clinical benefit of SGLT-2is 
compared to oGLDs was highly consistent across a 
number of prespecified subgroups, including age, sex, 
co-morbidities and use of various cardiovascular and 
anti-hyperglycemic agents. The results of this study, 
therefore, extend findings from prior CVD-REAL anal-
yses and from the SGLT-2i inhibitor clinical trials in a 
broader, more ethnically diverse population from 13 
countries.
Despite the significant cardiovascular benefits of 
SGLT-2i therapy reported in CVOTs and comparative 
effectiveness studies [10–12, 15, 16, 24–26], previous 
single country studies have shown that only a small pro-
portion of people meeting the criteria for the CVOTs 
are prescribed these therapies [27, 28]. The DISCOVER 
study of 37 countries with 14,668 participants showed 
that, overall, the prescriptions for SGLT-2i were low dur-
ing the study period 2014–2016, but also showed varia-
tions across continents [29]. In our study, assessment of 
the prescribing trends in the pre-matched patients from 
2012 to 2017 demonstrated that, overall, use of SGLT-2i 
has increased since 2013, from around 3% of all new ini-
tiations in 2013 to about 15% in 2017; although this pro-
portion remains low overall despite the evidence of the 
benefits of SGLT-2i. There were large variations between 
countries and over time, with the steepest increases in 
prescribing of SGLT-2i over this period seen in Canada 
and Israel. Recent data from the UK has also shown slow 
but steady increases in prescriptions for SGLT-2i as sec-
ond-line therapy to metformin from 2014 to 2017 [30].
The populations of the SGLT-2i CVOTs differed in 
the proportions of patients with established CVD that 
were recruited. The EMPA-REG, CANVAS Programme 
and the DECLARE-TIMI 58 trials included 100%, 65.6% 
and 37.4%, respectively, people with type 2 diabetes 
and established atherosclerotic CVD, with the remain-
der having risk factors for CVD [10, 11, 31]. A meta-
analysis of these three trials, with 34,322 patients and 
3342 major cardiovascular events found that compared 
to placebo, SGLT-2i reduced major adverse cardiovas-
cular events (cardiovascular death, myocardial infarc-
tion or stroke) by around 11% overall (HR 0.89, 95% CI 
0.83–0.96), with benefit seen in those with established 
atherosclerotic CVD [14]. Similarly the meta-analysis 
also demonstrated a benefit with SGLT-2i against the 
risk of cardiovascular deaths or HHF (HR 0.77, 95% CI 
0.71–0.84), and this benefit was seen across those with 
and without established CVD [14]. The results from 
this analysis of the CVD-REAL data, where the propor-
tion of participants with established CVD was much 
lower at just over 30%, complement the findings from 
Fig. 2 Pooled hazard ratios for the outcomes of hospitalization for heart failure, all‑cause death, composite of hospitalization for heart 
failure or all‑cause death, myocardial infarction, and stroke (Intent‑to‑treat analysis; unadjusted). ACD all‑cause death, HF heart failure, oGLD other 
glucose‑lowering drug, PY patient–years, SGLT-2i sodium–glucose cotransporter‑2 inhibitor
Page 8 of 15Khunti et al. Cardiovasc Diabetol          (2021) 20:159 
the CVOTs, and are similar to those seen in previous 
observational studies [24–26], thus further support-
ing the benefits of SGLT-2i in improving cardiovascu-
lar outcomes across a broad patient population. As one 
would expect, the absolute risks reductions are lower 
for those without versus with established CVD, yet the 
relative risk reductions are similar in both groups. The 
difference in the patient populations included in com-
parative-effectiveness studies and the CVOTs (where 
strict inclusion criteria are used), may explain some 
of the difference in magnitude of benefit seen between 
these studies.
There are a number of strengths in our study. This 
is the largest comparative effectiveness study of any 
Fig. 3 Pooled hazard ratios for A hospitalization for heart failure, B all‑cause death, C composite of hospitalization for heart failure or all‑cause 
death, D myocardial infarction, and E stroke stratified by subgroups (Intent‑to‑treat analysis; adjusted). Event rate, events per 100‑person years; 
ACE angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, oGLD other glucose‑lowering drug, SGLT-2i sodium–glucose 
cotransporter‑2 inhibitor
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glucose-lowering therapy to date with over 880,000 
propensity-matched patients from a pooled population 
from 13 countries with different healthcare systems. 
Despite a lower cardiovascular risk population, we had 
a very large number of events in view of the size of the 
study cohort, allowing adequate power for multiple 
subgroup analyses. When considering the number of 
all-cause deaths there were 10,252 events in our study 
compared to 5216 in CVD-REAL 2; while in the CVOTs 
there were 463 events in EMPA-REG OUTCOME; 681 
events in the CANVAS Programme; and 1099 in the 
DECLARE-TIMI 58 study [10–12, 15, 16]. This is a 
major strength of real-world comparative-effectiveness 
studies, as this large number of events in a broad popu-
lation would not be feasible in a randomized controlled 
trial. As with other CVD-REAL studies, we found no 
geographic heterogeneity in outcomes from the 13 
countries with the direction of the association for the 
Fig. 3 continued
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benefits for SGLT-2i similar in all countries; and as 
some countries or regions favor specific agents (such as 
dapagliflozin in South Korea or canagliflozin the USA) 
this suggests generally similar effects for SGLT-2is con-
tributing to this study.
These findings should be considered in light of some 
important limitations. Despite using robust statistical 
techniques including propensity score matching, the pos-
sibility of residual unmeasured confounding cannot be 
excluded. The data used in this analysis did not include 
important patientlevel data such as risk factor control, 
or comprehensive comorbidity data at baseline for some 
of the countries. In Japan and Singapore only in-hospital 
deaths were included. However, as most fatal events in 
these countries occur in hospital [20, 21], and the esti-
mates for the outcomes were directionally similar to the 
other countries, where capture of the mortality data was 
more comprehensive, the results for all-cause death in 
these countries are consistent with our findings in other 
participating countries. The countries included in this 
Fig. 3 continued
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study were all high-income, and therefore these findings 
may not be applicable to all patient populations. Safety of 
SGLT-2i versus oGLD was not assessed in our analysis; 
however, other randomized controlled trials and real-
world studies have confirmed the relative safety of the 
SGLT-2i class [32]. While we included a large numbers 
of patients, the overall follow-up was relatively short 
(just over 12  months) given the relatively recent intro-
duction of SGLT-2i. However, this is the longest length 
of follow-up across all previous CVD-REAL studies, and 
is similar to recently published comparative effective-
ness studies with a smaller cohort of patients, with find-
ings consistent with ours [24–26]. Longer term follow-up 
would be informative to evaluate the outcomes over time.
Fig. 3 continued
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Conclusion
The initiation of SGLT-2i as compared with other glu-
cose-lowering drugs in routine clinical practice is associ-
ated with decreased risk of heart failure, all-cause death, 
myocardial infarction and stroke. The results of this large 
comparative effectiveness study with a broader, globally 
diverse population complement and extend the findings 
of completed randomized controlled trials.
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